Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry W Herr

Showing results (221-230 of 230) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 230 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II TrialSamuel A Funt, Michael Lattanzi, Karissa Whiting, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2024
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024Thomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyThomas W Flaig, Philippe E Spiess, Neeraj Agarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial CarcinomaJonathan A Coleman, Wesley Yip, Nathan C Wong, et al.
JCO Precision Oncology|May 1, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder CancerAndrew T Lenis, Karissa Whiting, Vignesh Ravichandran, et al.
European Urology|September 26, 2025
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded CohortViranda H Jayalath, Melissa Assel, Gopa Iyer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2018
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018Thomas W Flaig, Philippe E Spiess, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2017
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in OncologyPhilippe E Spiess, Neeraj Agarwal, Rick Bangs, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016Peter E Clark, Philippe E Spiess, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 10, 2022
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022Thomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Pageof 23

Showing results (221-230 of 230) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 230 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II TrialSamuel A Funt, Michael Lattanzi, Karissa Whiting, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2024
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024Thomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyThomas W Flaig, Philippe E Spiess, Neeraj Agarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial CarcinomaJonathan A Coleman, Wesley Yip, Nathan C Wong, et al.
JCO Precision Oncology|May 1, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder CancerAndrew T Lenis, Karissa Whiting, Vignesh Ravichandran, et al.
European Urology|September 26, 2025
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded CohortViranda H Jayalath, Melissa Assel, Gopa Iyer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2018
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018Thomas W Flaig, Philippe E Spiess, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2017
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in OncologyPhilippe E Spiess, Neeraj Agarwal, Rick Bangs, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016Peter E Clark, Philippe E Spiess, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 10, 2022
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022Thomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Pageof 23